Yale University researcher Elisabetta Ullu died earlier this month of breast cancer.
Among Ullu's achievements was the discovery of RNAi in the protozoan parasite Trypanosoma brucei. According to Yale, she also contributed to the development of tools and techniques for manipulating the gene-silencing technology.
She was a member of the Genome and Tropical Medicine and Parasitology Study Sections of the National Institutes of Health, and was co-Director of the NIH training grant in Molecular Parasitology at Yale.
She is survived by her husband and research partner Christian Tschudi, as well as family in Switzerland and Italy.
Mirna Therapeutics has appointed Lawrence Alleva to its board of directors.
Alleva is a former partner at PricewaterhouseCoopers.
Alnylam Pharmaceuticals has appointed Karen Anderson as chief human resources officer. The company has also named Marko Kozul as vice president of strategy, and Laurie Keating as its general counsel.
Anderson previously worked at Biogen Idex as vice president of human resources for R&D and corporate development. Before that, she was vice president of human resources for Pfizer.
Kozul previously served as a biotechnology analyst for Leerink Partners, covering companies including Alnylam. Before that, he held analyst positions at ThinkEquity Partners and Jefferies & Company.
Keating most recently served as general counsel for Millennium Pharmaceuticals. She also co-founded and served as CEO of Hydra Biosciences.